• Novel strategies to unleash anticancer immunity (2023). Society for the Immunotherapy of Cancer, 38th Annual SITC Meeting. San Diego (USA).
• Radiotherapy as a combinatorial partner for targeted therapy in HR+ breast cancer (2023). SEOR, 2023 Annual SEOR Symposium. Madrid (Spain). Keynote
• Cellular mechanisms underlying the immunogenicity of RT in clinically relevant oncological settings (2023). ECDO-EATI, 1st Annual ECDO-EATI Joint Conference on Cell Death. Paris (France).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in HR+ breast cancer (2023). ECDO-EATI, 44º Congreso de la Sociedad Española de Inmunología. Bilbao (Spain). Keynote
• Immunogenic cell death driven by radiotherapy – Mechanisms and implications (2023). WCMC-Gustave Roussy, 7th International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad7). Paris (France).
• Radiotherapy as a combinatorial partner for immunotherapy and targeted therapy in breast cancer (2023). GETICA, IX Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Madrid (Spain). Keynote
• Harnessing radiotherapy to unlock the full potential of cancer immunotherapy (2023). Martin Luther University Halle‐Wittenberg, 17th Tumor Immunology Meets Oncology (TIMO) Meeting. Halle (Germany).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2022). CIMA, Cancer immunotherapy mechanisms in action – International Seminar. Pamplona (Spain).
• IL17-producing γδ T cells promote resistance to CDK46 inhibitors in HR+HER2- breast cancer (2022). SITC, 37th Annual Meeting of the Society for Immunotherapy of Cancer. Boston (USA).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2022). Martin Luther University Halle‐Wittenberg, 16th Tumor Immunology Meets Oncology (TIMO) Meeting. Halle (Germany).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2022). Hellenic Society of Immuno-Oncology, 8th Symposium on Advances in Cancer Immunology and Immunotherapy. Athens (Greece). Keynote
• Mitochondrial apoptosis regulates immune responses driven by radiation therapy (2022). Gordon Research Conferences, Cell Death-Associated Inflammation in Disease. Les Diablerets (Switzerland).
• Harnessing radiation therapy to improve the efficacy of immunotherapy (2022). GETICA, VIII Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Barcelona (Spain). Keynote
• Low-dose RT as a tool to boost the efficacy of CAR T cell therapy (2021). Forbeck Forum, Immunotherapies and mechanisms of immune escape. Denver (USA).
• Mitochondrial DNA in innate immune signaling driven by radiation therapy (2021). Associazione Biologia Cellulare e Differenziamento (ABCD), Biennial Congress of the Italian Society of Cell Biology. (Virtual).
• Apoptotic caspases – Key regulators of the interaction between radiotherapy and anticancer immunity (2021). SEOR, First Virtual Congress of the Spanish Society for Radiation Oncology. (Virtual).
• Mitochondrial control of anticancer immune responses driven by radiation (2021). EATI, The Paris Immuno-Oncology 2021 Conference. (Virtual).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2021). Creative Educational Concepts and SITC, 7th Annual Immuno-Oncology Young Investigators’ Forum. Houston (USA).
• Radiotherapy as a tool to boost immunostimulation by CDK4/6 inhibitors in ER+ breast cancer (2021). GETICA, VII Foro de Inmunologia Translacional y Inmunoterapia del Cancer. (Virtual).
• Apoptotic caspases – Key regulators of the interaction between radiotherapy and anticancer immunity (2021). European Society for RadioTherapy and Oncology, 40th Annual Meeting of the European Society for RadioTherapy and Oncology. (Virtual).
• Harnessing radiation therapy to boost the efficacy of cancer (immuno)therapy (2021). WCMC-Gustave Roussy, 5th International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad5). Paris (France).
• MPA/DMBA-driven mammary carcinomas as a model of luminal B breast cancer (2021). Hanson Wade, 5th PREDiCT Tumor Models Summit. (Virtual).
• Autophagy and immunologic cell death as they relate to anticancer therapies (2020). RRS, NCI and NASA, Particle Radiobiology in Space and Oncology Symposia. Bethesda (USA). Cancelled*
• Immunosurveillance of HR+ breast cancer – Prophylactic and therapeutic effects of nicotinamide (2020). GETICA, VI Foro de Inmunologia Translacional y Inmunoterapia del Cancer. (Virtual). Keynote
• mtDNA drives abscopal responses to RT that are inhibited by autophagy and caspases (2020). WCMC-Gustave Roussy, 5th International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad5). Paris (France). Cancelled*
• Autophagy inhibition as a partner strategy to inflame cold tumors (2019). GETICA, V Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Madrid (Spain).
• Modulating autophagy as an example of precision cancer (immuno)therapy (2019). Trinity Translational Medicine Institute- St. James’s Hospital, 11th International Cancer Conference. Dublin (Ireland).
• Modulating autophagy as an example of precision cancer (immuno)therapy (2019). Universidade Federal de São Paulo, Oncology Symposium. Sao Paulo (Brazil).
• mtDNA drives abscopal responses to RT that are inhibited by autophagy (2019). SfRBM, 25th SfRBM Annual Conference. Las Vegas (USA).
• mtDNA drives abscopal responses to RT that are inhibited by autophagy (2019). CRI-CIMT-EATI-AACR, 5th International Cancer Immunotherapy Conference (CICON19). Paris (France).
• NK cells beat T cells at breast cancer control (2019). Weizmann Institute, NK cells in Cancer: The next Breakthrough? Conference. Tel Aviv (Israel). Keynote
• Role of adaptive stress responses in the therapeutic activity of ECP (2019). ASFA, ASFA 2019 Annual Meeting. Portland (USA).
• Autophagy in anticancer immunity (2018). AACR, 109th AACR Annual Meeting. Chicago (USA).
• Autophagy in cancer (immuno)therapy (2018). WCMC-Gustave Roussy, 3rd International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad3). Paris (France).
• Autophagy modulation for precision cancer immunotherapy (2018). Universidad Francisco de Vitoria, Desafio Oncologico 9: Mas alla del genoma Meeting. Valencia (Spain).
• Autophagy, danger, death and immunity in anticancer therapy (2018). ICDS, 25th International Cell Death Society Meeting. Seoul (South Korea).
• Immunogenic cell death in radiation therapy and immunotherapy (2018). ESTRO, 37th European Society for Therapeutic Radiology and Oncology Meeting. Barcelona (Spain).
• Should radiation therapy be repurposed as an in situ vaccination in cancer therapy? (2018). GETICA, IV Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Madrid (Spain).
• ATP at the interface between cellular bioenergetics and organismal homeostasis (2017). Nature Medicine-Helmholtz Diabetes Center, 5th Helmholtz-Nature Medicine Diabetes Conference. Munich (Germany).
• Autophagy and radiation (2017). WCMC-Gustave Roussy, 2nd International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad2). New York (USA).
• Cell death – Basic concepts and common misconception (2017). RRS, 63rd Annual Meeting of the Radiation Research Society. Cancun (Mexico).
• Immunogenic cell death – A story of intracellular stress and organismal homeostasis (2017). GETICA, III Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Sevilla (Spain).
• Inside-Out – A story of intracellular stress and organismal homeostasis (2017). Cambridge Healthtech Institute, World Preclinical Congress. Boston (USA). Keynote
• Inside-Out – A story of intracellular stress and organismal homeostasis (2017). International Society of Cancer Metabolism, Targeting the Metabolic Deregulation of Cancer: A Novel Pharmacological Approach Conference. Padova (Italy).
• Stress, death and immunity in cancer chemotherapy (2017). Johns Hopkins University, Immunometabolic Adjuvants for Cancer Therapy Conference. Baltimore (USA).
• Immunogenic cell death – The Archimedean lever (2016). GETICA, II Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Sevilla (Spain).
• Inside-Out – A story of intracellular stress and organismal homeostasis (2016). IUIS-ALAI-SMI, First International IUIS-ALAI-SMI Oncoimmunology Mexico Course. San Miguel de Allende (Mexico).
• Mitochondrial control of stress responses and danger signalling (2016). FISV, XIV Congress of the Italian Federation of Life Sciences (FISV). Rome (Italy).
• Stress, death and immunity in cancer chemotherapy (2016). SEI, 39º Congreso de la Sociedad Española de Inmunología. Alicante (Spain). Keynote
• Stress, death, immunity and cancer therapy (2016). Cambridge Healthtech Institute, World Preclinical Congress Europe. Lisbon (Portugal). Keynote
• Stress, death, immunity and cancer therapy (2016). University of Siena-AOC Siena, 3rd International Cancer Vaccine Meeting. Siena (Italy).
• Stress, death, immunity and radiation therapy (2016). AACR, 107th AACR Annual Meeting. New Orleans (USA).
• Immunogenic cell death in anti-cancer therapy (2015). SITC, 11th Tumor Immunology Meets Oncology (TIMO) Meeting. Halle (Germany).
• Mitochondria, p53 and cancer (2011). Europa Organisation, Euro Cancer 2011. Paris (France).
• Methods for the detection of cell death (2010). ECDO, 18th Euroconference on Apoptosis. Ghent (Belgium).
• miRNA-dependent regulation of apoptosis in NSCLC cells (2010). ERI-ICP, 1st Conference of the European Research Institute for Integrated Cellular Pathology. Paris (France).
• Triple C – A systems biology study of apoptosis (2009). EPITRON Consortium, 2nd EPITRON Brainstorming meeting. Budva (Montenegro).

*Due to Covid19

• Novel strategies to unleash anticancer immunity (2023). Society for the Immunotherapy of Cancer, 38th Annual SITC Meeting. San Diego (USA).
• Radiotherapy as a combinatorial partner for targeted therapy in HR+ breast cancer (2023). SEOR, 2023 Annual SEOR Symposium. Madrid (Spain). Keynote
• Cellular mechanisms underlying the immunogenicity of RT in clinically relevant oncological settings (2023). ECDO-EATI, 1st Annual ECDO-EATI Joint Conference on Cell Death. Paris (France).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in HR+ breast cancer (2023). ECDO-EATI, 44º Congreso de la Sociedad Española de Inmunología. Bilbao (Spain). Keynote
• Immunogenic cell death driven by radiotherapy – Mechanisms and implications (2023). WCMC-Gustave Roussy, 7th International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad7). Paris (France).
• Radiotherapy as a combinatorial partner for immunotherapy and targeted therapy in breast cancer (2023). GETICA, IX Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Madrid (Spain). Keynote
• Harnessing radiotherapy to unlock the full potential of cancer immunotherapy (2023). Martin Luther University Halle‐Wittenberg, 17th Tumor Immunology Meets Oncology (TIMO) Meeting. Halle (Germany).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2022). CIMA, Cancer immunotherapy mechanisms in action – International Seminar. Pamplona (Spain).
• IL17-producing γδ T cells promote resistance to CDK46 inhibitors in HR+HER2- breast cancer (2022). SITC, 37th Annual Meeting of the Society for Immunotherapy of Cancer. Boston (USA).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2022). Martin Luther University Halle‐Wittenberg, 16th Tumor Immunology Meets Oncology (TIMO) Meeting. Halle (Germany).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2022). Hellenic Society of Immuno-Oncology, 8th Symposium on Advances in Cancer Immunology and Immunotherapy. Athens (Greece). Keynote
• Mitochondrial apoptosis regulates immune responses driven by radiation therapy (2022). Gordon Research Conferences, Cell Death-Associated Inflammation in Disease. Les Diablerets (Switzerland).
• Harnessing radiation therapy to improve the efficacy of immunotherapy (2022). GETICA, VIII Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Barcelona (Spain). Keynote
• Low-dose RT as a tool to boost the efficacy of CAR T cell therapy (2021). Forbeck Forum, Immunotherapies and mechanisms of immune escape. Denver (USA).
• Mitochondrial DNA in innate immune signaling driven by radiation therapy (2021). Associazione Biologia Cellulare e Differenziamento (ABCD), Biennial Congress of the Italian Society of Cell Biology. (Virtual).
• Apoptotic caspases – Key regulators of the interaction between radiotherapy and anticancer immunity (2021). SEOR, First Virtual Congress of the Spanish Society for Radiation Oncology. (Virtual).
• Mitochondrial control of anticancer immune responses driven by radiation (2021). EATI, The Paris Immuno-Oncology 2021 Conference. (Virtual).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2021). Creative Educational Concepts and SITC, 7th Annual Immuno-Oncology Young Investigators’ Forum. Houston (USA).
• Radiotherapy as a tool to boost immunostimulation by CDK4/6 inhibitors in ER+ breast cancer (2021). GETICA, VII Foro de Inmunologia Translacional y Inmunoterapia del Cancer. (Virtual).
• Apoptotic caspases – Key regulators of the interaction between radiotherapy and anticancer immunity (2021). European Society for RadioTherapy and Oncology, 40th Annual Meeting of the European Society for RadioTherapy and Oncology. (Virtual).
• Harnessing radiation therapy to boost the efficacy of cancer (immuno)therapy (2021). WCMC-Gustave Roussy, 5th International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad5). Paris (France).
• MPA/DMBA-driven mammary carcinomas as a model of luminal B breast cancer (2021). Hanson Wade, 5th PREDiCT Tumor Models Summit. (Virtual).
• Autophagy and immunologic cell death as they relate to anticancer therapies (2020). RRS, NCI and NASA, Particle Radiobiology in Space and Oncology Symposia. Bethesda (USA). Cancelled*
• Immunosurveillance of HR+ breast cancer – Prophylactic and therapeutic effects of nicotinamide (2020). GETICA, VI Foro de Inmunologia Translacional y Inmunoterapia del Cancer. (Virtual). Keynote
• mtDNA drives abscopal responses to RT that are inhibited by autophagy and caspases (2020). WCMC-Gustave Roussy, 5th International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad5). Paris (France). Cancelled*
• Autophagy inhibition as a partner strategy to inflame cold tumors (2019). GETICA, V Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Madrid (Spain).
• Modulating autophagy as an example of precision cancer (immuno)therapy (2019). Trinity Translational Medicine Institute- St. James’s Hospital, 11th International Cancer Conference. Dublin (Ireland).
• Modulating autophagy as an example of precision cancer (immuno)therapy (2019). Universidade Federal de São Paulo, Oncology Symposium. Sao Paulo (Brazil).
• mtDNA drives abscopal responses to RT that are inhibited by autophagy (2019). SfRBM, 25th SfRBM Annual Conference. Las Vegas (USA).
• mtDNA drives abscopal responses to RT that are inhibited by autophagy (2019). CRI-CIMT-EATI-AACR, 5th International Cancer Immunotherapy Conference (CICON19). Paris (France).
• NK cells beat T cells at breast cancer control (2019). Weizmann Institute, NK cells in Cancer: The next Breakthrough? Conference. Tel Aviv (Israel). Keynote
• Role of adaptive stress responses in the therapeutic activity of ECP (2019). ASFA, ASFA 2019 Annual Meeting. Portland (USA).
• Autophagy in anticancer immunity (2018). AACR, 109th AACR Annual Meeting. Chicago (USA).
• Autophagy in cancer (immuno)therapy (2018). WCMC-Gustave Roussy, 3rd International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad3). Paris (France).
• Autophagy modulation for precision cancer immunotherapy (2018). Universidad Francisco de Vitoria, Desafio Oncologico 9: Mas alla del genoma Meeting. Valencia (Spain).
• Autophagy, danger, death and immunity in anticancer therapy (2018). ICDS, 25th International Cell Death Society Meeting. Seoul (South Korea).
• Immunogenic cell death in radiation therapy and immunotherapy (2018). ESTRO, 37th European Society for Therapeutic Radiology and Oncology Meeting. Barcelona (Spain).
• Should radiation therapy be repurposed as an in situ vaccination in cancer therapy? (2018). GETICA, IV Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Madrid (Spain).
• ATP at the interface between cellular bioenergetics and organismal homeostasis (2017). Nature Medicine-Helmholtz Diabetes Center, 5th Helmholtz-Nature Medicine Diabetes Conference. Munich (Germany).
• Autophagy and radiation (2017). WCMC-Gustave Roussy, 2nd International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad2). New York (USA).
• Cell death – Basic concepts and common misconception (2017). RRS, 63rd Annual Meeting of the Radiation Research Society. Cancun (Mexico).
• Immunogenic cell death – A story of intracellular stress and organismal homeostasis (2017). GETICA, III Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Sevilla (Spain).
• Inside-Out – A story of intracellular stress and organismal homeostasis (2017). Cambridge Healthtech Institute, World Preclinical Congress. Boston (USA). Keynote
• Inside-Out – A story of intracellular stress and organismal homeostasis (2017). International Society of Cancer Metabolism, Targeting the Metabolic Deregulation of Cancer: A Novel Pharmacological Approach Conference. Padova (Italy).
• Stress, death and immunity in cancer chemotherapy (2017). Johns Hopkins University, Immunometabolic Adjuvants for Cancer Therapy Conference. Baltimore (USA).
• Immunogenic cell death – The Archimedean lever (2016). GETICA, II Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Sevilla (Spain).
• Inside-Out – A story of intracellular stress and organismal homeostasis (2016). IUIS-ALAI-SMI, First International IUIS-ALAI-SMI Oncoimmunology Mexico Course. San Miguel de Allende (Mexico).
• Mitochondrial control of stress responses and danger signalling (2016). FISV, XIV Congress of the Italian Federation of Life Sciences (FISV). Rome (Italy).
• Stress, death and immunity in cancer chemotherapy (2016). SEI, 39º Congreso de la Sociedad Española de Inmunología. Alicante (Spain). Keynote
• Stress, death, immunity and cancer therapy (2016). Cambridge Healthtech Institute, World Preclinical Congress Europe. Lisbon (Portugal). Keynote
• Stress, death, immunity and cancer therapy (2016). University of Siena-AOC Siena, 3rd International Cancer Vaccine Meeting. Siena (Italy).
• Stress, death, immunity and radiation therapy (2016). AACR, 107th AACR Annual Meeting. New Orleans (USA).
• Immunogenic cell death in anti-cancer therapy (2015). SITC, 11th Tumor Immunology Meets Oncology (TIMO) Meeting. Halle (Germany).
• Mitochondria, p53 and cancer (2011). Europa Organisation, Euro Cancer 2011. Paris (France).
• Methods for the detection of cell death (2010). ECDO, 18th Euroconference on Apoptosis. Ghent (Belgium).
• miRNA-dependent regulation of apoptosis in NSCLC cells (2010). ERI-ICP, 1st Conference of the European Research Institute for Integrated Cellular Pathology. Paris (France).
• Triple C – A systems biology study of apoptosis (2009). EPITRON Consortium, 2nd EPITRON Brainstorming meeting. Budva (Montenegro).

*Due to Covid19

• Novel strategies to unleash anticancer immunity (2023). Society for the Immunotherapy of Cancer, 38th Annual SITC Meeting. San Diego (USA).
• Radiotherapy as a combinatorial partner for targeted therapy in HR+ breast cancer (2023). SEOR, 2023 Annual SEOR Symposium. Madrid (Spain). Keynote
• Cellular mechanisms underlying the immunogenicity of RT in clinically relevant oncological settings (2023). ECDO-EATI, 1st Annual ECDO-EATI Joint Conference on Cell Death. Paris (France).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in HR+ breast cancer (2023). ECDO-EATI, 44º Congreso de la Sociedad Española de Inmunología. Bilbao (Spain). Keynote
• Immunogenic cell death driven by radiotherapy – Mechanisms and implications (2023). WCMC-Gustave Roussy, 7th International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad7). Paris (France).
• Radiotherapy as a combinatorial partner for immunotherapy and targeted therapy in breast cancer (2023). GETICA, IX Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Madrid (Spain). Keynote
• Harnessing radiotherapy to unlock the full potential of cancer immunotherapy (2023). Martin Luther University Halle‐Wittenberg, 17th Tumor Immunology Meets Oncology (TIMO) Meeting. Halle (Germany).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2022). CIMA, Cancer immunotherapy mechanisms in action – International Seminar. Pamplona (Spain).
• IL17-producing γδ T cells promote resistance to CDK46 inhibitors in HR+HER2- breast cancer (2022). SITC, 37th Annual Meeting of the Society for Immunotherapy of Cancer. Boston (USA).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2022). Martin Luther University Halle‐Wittenberg, 16th Tumor Immunology Meets Oncology (TIMO) Meeting. Halle (Germany).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2022). Hellenic Society of Immuno-Oncology, 8th Symposium on Advances in Cancer Immunology and Immunotherapy. Athens (Greece). Keynote
• Mitochondrial apoptosis regulates immune responses driven by radiation therapy (2022). Gordon Research Conferences, Cell Death-Associated Inflammation in Disease. Les Diablerets (Switzerland).
• Harnessing radiation therapy to improve the efficacy of immunotherapy (2022). GETICA, VIII Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Barcelona (Spain). Keynote
• Low-dose RT as a tool to boost the efficacy of CAR T cell therapy (2021). Forbeck Forum, Immunotherapies and mechanisms of immune escape. Denver (USA).
• Mitochondrial DNA in innate immune signaling driven by radiation therapy (2021). Associazione Biologia Cellulare e Differenziamento (ABCD), Biennial Congress of the Italian Society of Cell Biology. (Virtual).
• Apoptotic caspases – Key regulators of the interaction between radiotherapy and anticancer immunity (2021). SEOR, First Virtual Congress of the Spanish Society for Radiation Oncology. (Virtual).
• Mitochondrial control of anticancer immune responses driven by radiation (2021). EATI, The Paris Immuno-Oncology 2021 Conference. (Virtual).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2021). Creative Educational Concepts and SITC, 7th Annual Immuno-Oncology Young Investigators’ Forum. Houston (USA).
• Radiotherapy as a tool to boost immunostimulation by CDK4/6 inhibitors in ER+ breast cancer (2021). GETICA, VII Foro de Inmunologia Translacional y Inmunoterapia del Cancer. (Virtual).
• Apoptotic caspases – Key regulators of the interaction between radiotherapy and anticancer immunity (2021). European Society for RadioTherapy and Oncology, 40th Annual Meeting of the European Society for RadioTherapy and Oncology. (Virtual).
• Harnessing radiation therapy to boost the efficacy of cancer (immuno)therapy (2021). WCMC-Gustave Roussy, 5th International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad5). Paris (France).
• MPA/DMBA-driven mammary carcinomas as a model of luminal B breast cancer (2021). Hanson Wade, 5th PREDiCT Tumor Models Summit. (Virtual).
• Autophagy and immunologic cell death as they relate to anticancer therapies (2020). RRS, NCI and NASA, Particle Radiobiology in Space and Oncology Symposia. Bethesda (USA). Cancelled*
• Immunosurveillance of HR+ breast cancer – Prophylactic and therapeutic effects of nicotinamide (2020). GETICA, VI Foro de Inmunologia Translacional y Inmunoterapia del Cancer. (Virtual). Keynote
• mtDNA drives abscopal responses to RT that are inhibited by autophagy and caspases (2020). WCMC-Gustave Roussy, 5th International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad5). Paris (France). Cancelled*
• Autophagy inhibition as a partner strategy to inflame cold tumors (2019). GETICA, V Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Madrid (Spain).
• Modulating autophagy as an example of precision cancer (immuno)therapy (2019). Trinity Translational Medicine Institute- St. James’s Hospital, 11th International Cancer Conference. Dublin (Ireland).
• Modulating autophagy as an example of precision cancer (immuno)therapy (2019). Universidade Federal de São Paulo, Oncology Symposium. Sao Paulo (Brazil).
• mtDNA drives abscopal responses to RT that are inhibited by autophagy (2019). SfRBM, 25th SfRBM Annual Conference. Las Vegas (USA).
• mtDNA drives abscopal responses to RT that are inhibited by autophagy (2019). CRI-CIMT-EATI-AACR, 5th International Cancer Immunotherapy Conference (CICON19). Paris (France).
• NK cells beat T cells at breast cancer control (2019). Weizmann Institute, NK cells in Cancer: The next Breakthrough? Conference. Tel Aviv (Israel). Keynote
• Role of adaptive stress responses in the therapeutic activity of ECP (2019). ASFA, ASFA 2019 Annual Meeting. Portland (USA).
• Autophagy in anticancer immunity (2018). AACR, 109th AACR Annual Meeting. Chicago (USA).
• Autophagy in cancer (immuno)therapy (2018). WCMC-Gustave Roussy, 3rd International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad3). Paris (France).
• Autophagy modulation for precision cancer immunotherapy (2018). Universidad Francisco de Vitoria, Desafio Oncologico 9: Mas alla del genoma Meeting. Valencia (Spain).
• Autophagy, danger, death and immunity in anticancer therapy (2018). ICDS, 25th International Cell Death Society Meeting. Seoul (South Korea).
• Immunogenic cell death in radiation therapy and immunotherapy (2018). ESTRO, 37th European Society for Therapeutic Radiology and Oncology Meeting. Barcelona (Spain).
• Should radiation therapy be repurposed as an in situ vaccination in cancer therapy? (2018). GETICA, IV Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Madrid (Spain).
• ATP at the interface between cellular bioenergetics and organismal homeostasis (2017). Nature Medicine-Helmholtz Diabetes Center, 5th Helmholtz-Nature Medicine Diabetes Conference. Munich (Germany).
• Autophagy and radiation (2017). WCMC-Gustave Roussy, 2nd International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad2). New York (USA).
• Cell death – Basic concepts and common misconception (2017). RRS, 63rd Annual Meeting of the Radiation Research Society. Cancun (Mexico).
• Immunogenic cell death – A story of intracellular stress and organismal homeostasis (2017). GETICA, III Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Sevilla (Spain).
• Inside-Out – A story of intracellular stress and organismal homeostasis (2017). Cambridge Healthtech Institute, World Preclinical Congress. Boston (USA). Keynote
• Inside-Out – A story of intracellular stress and organismal homeostasis (2017). International Society of Cancer Metabolism, Targeting the Metabolic Deregulation of Cancer: A Novel Pharmacological Approach Conference. Padova (Italy).
• Stress, death and immunity in cancer chemotherapy (2017). Johns Hopkins University, Immunometabolic Adjuvants for Cancer Therapy Conference. Baltimore (USA).
• Immunogenic cell death – The Archimedean lever (2016). GETICA, II Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Sevilla (Spain).
• Inside-Out – A story of intracellular stress and organismal homeostasis (2016). IUIS-ALAI-SMI, First International IUIS-ALAI-SMI Oncoimmunology Mexico Course. San Miguel de Allende (Mexico).
• Mitochondrial control of stress responses and danger signalling (2016). FISV, XIV Congress of the Italian Federation of Life Sciences (FISV). Rome (Italy).
• Stress, death and immunity in cancer chemotherapy (2016). SEI, 39º Congreso de la Sociedad Española de Inmunología. Alicante (Spain). Keynote
• Stress, death, immunity and cancer therapy (2016). Cambridge Healthtech Institute, World Preclinical Congress Europe. Lisbon (Portugal). Keynote
• Stress, death, immunity and cancer therapy (2016). University of Siena-AOC Siena, 3rd International Cancer Vaccine Meeting. Siena (Italy).
• Stress, death, immunity and radiation therapy (2016). AACR, 107th AACR Annual Meeting. New Orleans (USA).
• Immunogenic cell death in anti-cancer therapy (2015). SITC, 11th Tumor Immunology Meets Oncology (TIMO) Meeting. Halle (Germany).
• Mitochondria, p53 and cancer (2011). Europa Organisation, Euro Cancer 2011. Paris (France).
• Methods for the detection of cell death (2010). ECDO, 18th Euroconference on Apoptosis. Ghent (Belgium).
• miRNA-dependent regulation of apoptosis in NSCLC cells (2010). ERI-ICP, 1st Conference of the European Research Institute for Integrated Cellular Pathology. Paris (France).
• Triple C – A systems biology study of apoptosis (2009). EPITRON Consortium, 2nd EPITRON Brainstorming meeting. Budva (Montenegro).

*Due to Covid19

• Novel strategies to unleash anticancer immunity (2023). Society for the Immunotherapy of Cancer, 38th Annual SITC Meeting. San Diego (USA).
• Radiotherapy as a combinatorial partner for targeted therapy in HR+ breast cancer (2023). SEOR, 2023 Annual SEOR Symposium. Madrid (Spain). Keynote
• Cellular mechanisms underlying the immunogenicity of RT in clinically relevant oncological settings (2023). ECDO-EATI, 1st Annual ECDO-EATI Joint Conference on Cell Death. Paris (France).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in HR+ breast cancer (2023). ECDO-EATI, 44º Congreso de la Sociedad Española de Inmunología. Bilbao (Spain). Keynote
• Immunogenic cell death driven by radiotherapy – Mechanisms and implications (2023). WCMC-Gustave Roussy, 7th International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad7). Paris (France).
• Radiotherapy as a combinatorial partner for immunotherapy and targeted therapy in breast cancer (2023). GETICA, IX Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Madrid (Spain). Keynote
• Harnessing radiotherapy to unlock the full potential of cancer immunotherapy (2023). Martin Luther University Halle‐Wittenberg, 17th Tumor Immunology Meets Oncology (TIMO) Meeting. Halle (Germany).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2022). CIMA, Cancer immunotherapy mechanisms in action – International Seminar. Pamplona (Spain).
• IL17-producing γδ T cells promote resistance to CDK46 inhibitors in HR+HER2- breast cancer (2022). SITC, 37th Annual Meeting of the Society for Immunotherapy of Cancer. Boston (USA).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2022). Martin Luther University Halle‐Wittenberg, 16th Tumor Immunology Meets Oncology (TIMO) Meeting. Halle (Germany).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2022). Hellenic Society of Immuno-Oncology, 8th Symposium on Advances in Cancer Immunology and Immunotherapy. Athens (Greece). Keynote
• Mitochondrial apoptosis regulates immune responses driven by radiation therapy (2022). Gordon Research Conferences, Cell Death-Associated Inflammation in Disease. Les Diablerets (Switzerland).
• Harnessing radiation therapy to improve the efficacy of immunotherapy (2022). GETICA, VIII Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Barcelona (Spain). Keynote
• Low-dose RT as a tool to boost the efficacy of CAR T cell therapy (2021). Forbeck Forum, Immunotherapies and mechanisms of immune escape. Denver (USA).
• Mitochondrial DNA in innate immune signaling driven by radiation therapy (2021). Associazione Biologia Cellulare e Differenziamento (ABCD), Biennial Congress of the Italian Society of Cell Biology. (Virtual).
• Apoptotic caspases – Key regulators of the interaction between radiotherapy and anticancer immunity (2021). SEOR, First Virtual Congress of the Spanish Society for Radiation Oncology. (Virtual).
• Mitochondrial control of anticancer immune responses driven by radiation (2021). EATI, The Paris Immuno-Oncology 2021 Conference. (Virtual).
• Immunological mechanisms of resistance to CDK4/6 inhibitors in breast cancer (2021). Creative Educational Concepts and SITC, 7th Annual Immuno-Oncology Young Investigators’ Forum. Houston (USA).
• Radiotherapy as a tool to boost immunostimulation by CDK4/6 inhibitors in ER+ breast cancer (2021). GETICA, VII Foro de Inmunologia Translacional y Inmunoterapia del Cancer. (Virtual).
• Apoptotic caspases – Key regulators of the interaction between radiotherapy and anticancer immunity (2021). European Society for RadioTherapy and Oncology, 40th Annual Meeting of the European Society for RadioTherapy and Oncology. (Virtual).
• Harnessing radiation therapy to boost the efficacy of cancer (immuno)therapy (2021). WCMC-Gustave Roussy, 5th International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad5). Paris (France).
• MPA/DMBA-driven mammary carcinomas as a model of luminal B breast cancer (2021). Hanson Wade, 5th PREDiCT Tumor Models Summit. (Virtual).
• Autophagy and immunologic cell death as they relate to anticancer therapies (2020). RRS, NCI and NASA, Particle Radiobiology in Space and Oncology Symposia. Bethesda (USA). Cancelled*
• Immunosurveillance of HR+ breast cancer – Prophylactic and therapeutic effects of nicotinamide (2020). GETICA, VI Foro de Inmunologia Translacional y Inmunoterapia del Cancer. (Virtual). Keynote
• mtDNA drives abscopal responses to RT that are inhibited by autophagy and caspases (2020). WCMC-Gustave Roussy, 5th International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad5). Paris (France). Cancelled*
• Autophagy inhibition as a partner strategy to inflame cold tumors (2019). GETICA, V Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Madrid (Spain).
• Modulating autophagy as an example of precision cancer (immuno)therapy (2019). Trinity Translational Medicine Institute- St. James’s Hospital, 11th International Cancer Conference. Dublin (Ireland).
• Modulating autophagy as an example of precision cancer (immuno)therapy (2019). Universidade Federal de São Paulo, Oncology Symposium. Sao Paulo (Brazil).
• mtDNA drives abscopal responses to RT that are inhibited by autophagy (2019). SfRBM, 25th SfRBM Annual Conference. Las Vegas (USA).
• mtDNA drives abscopal responses to RT that are inhibited by autophagy (2019). CRI-CIMT-EATI-AACR, 5th International Cancer Immunotherapy Conference (CICON19). Paris (France).
• NK cells beat T cells at breast cancer control (2019). Weizmann Institute, NK cells in Cancer: The next Breakthrough? Conference. Tel Aviv (Israel). Keynote
• Role of adaptive stress responses in the therapeutic activity of ECP (2019). ASFA, ASFA 2019 Annual Meeting. Portland (USA).
• Autophagy in anticancer immunity (2018). AACR, 109th AACR Annual Meeting. Chicago (USA).
• Autophagy in cancer (immuno)therapy (2018). WCMC-Gustave Roussy, 3rd International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad3). Paris (France).
• Autophagy modulation for precision cancer immunotherapy (2018). Universidad Francisco de Vitoria, Desafio Oncologico 9: Mas alla del genoma Meeting. Valencia (Spain).
• Autophagy, danger, death and immunity in anticancer therapy (2018). ICDS, 25th International Cell Death Society Meeting. Seoul (South Korea).
• Immunogenic cell death in radiation therapy and immunotherapy (2018). ESTRO, 37th European Society for Therapeutic Radiology and Oncology Meeting. Barcelona (Spain).
• Should radiation therapy be repurposed as an in situ vaccination in cancer therapy? (2018). GETICA, IV Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Madrid (Spain).
• ATP at the interface between cellular bioenergetics and organismal homeostasis (2017). Nature Medicine-Helmholtz Diabetes Center, 5th Helmholtz-Nature Medicine Diabetes Conference. Munich (Germany).
• Autophagy and radiation (2017). WCMC-Gustave Roussy, 2nd International Conference on Immunotherapy Radiotherapy Combinations (ImmunoRad2). New York (USA).
• Cell death – Basic concepts and common misconception (2017). RRS, 63rd Annual Meeting of the Radiation Research Society. Cancun (Mexico).
• Immunogenic cell death – A story of intracellular stress and organismal homeostasis (2017). GETICA, III Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Sevilla (Spain).
• Inside-Out – A story of intracellular stress and organismal homeostasis (2017). Cambridge Healthtech Institute, World Preclinical Congress. Boston (USA). Keynote
• Inside-Out – A story of intracellular stress and organismal homeostasis (2017). International Society of Cancer Metabolism, Targeting the Metabolic Deregulation of Cancer: A Novel Pharmacological Approach Conference. Padova (Italy).
• Stress, death and immunity in cancer chemotherapy (2017). Johns Hopkins University, Immunometabolic Adjuvants for Cancer Therapy Conference. Baltimore (USA).
• Immunogenic cell death – The Archimedean lever (2016). GETICA, II Foro de Inmunologia Translacional y Inmunoterapia del Cancer. Sevilla (Spain).
• Inside-Out – A story of intracellular stress and organismal homeostasis (2016). IUIS-ALAI-SMI, First International IUIS-ALAI-SMI Oncoimmunology Mexico Course. San Miguel de Allende (Mexico).
• Mitochondrial control of stress responses and danger signalling (2016). FISV, XIV Congress of the Italian Federation of Life Sciences (FISV). Rome (Italy).
• Stress, death and immunity in cancer chemotherapy (2016). SEI, 39º Congreso de la Sociedad Española de Inmunología. Alicante (Spain). Keynote
• Stress, death, immunity and cancer therapy (2016). Cambridge Healthtech Institute, World Preclinical Congress Europe. Lisbon (Portugal). Keynote
• Stress, death, immunity and cancer therapy (2016). University of Siena-AOC Siena, 3rd International Cancer Vaccine Meeting. Siena (Italy).
• Stress, death, immunity and radiation therapy (2016). AACR, 107th AACR Annual Meeting. New Orleans (USA).
• Immunogenic cell death in anti-cancer therapy (2015). SITC, 11th Tumor Immunology Meets Oncology (TIMO) Meeting. Halle (Germany).
• Mitochondria, p53 and cancer (2011). Europa Organisation, Euro Cancer 2011. Paris (France).
• Methods for the detection of cell death (2010). ECDO, 18th Euroconference on Apoptosis. Ghent (Belgium).
• miRNA-dependent regulation of apoptosis in NSCLC cells (2010). ERI-ICP, 1st Conference of the European Research Institute for Integrated Cellular Pathology. Paris (France).
• Triple C – A systems biology study of apoptosis (2009). EPITRON Consortium, 2nd EPITRON Brainstorming meeting. Budva (Montenegro).

*Due to Covid19